Skip to main content
SpringerLink
Log in

The expression of URGCP gene in prostate cancer cell lines: correlation with rapamycin

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Molecular targets in prostate cancer are continually being explored, for which there are currently few therapeutic options. Rapamycin (RPM) is an antifungal macrolide antibiotic isolated from Streptomyces hygroscopicus which can inhibit the G1 to S transition. URGCP (upregulator of cell proliferation) is a novel gene located on chromosome 7p13. We aimed to investigate the role of URGCP gene expression changes in PC3, DU145, and LNCAP cell lines with/out RPM. Average cell viability and cytotoxic effect of rapamycin were investigated at 24 h intervals for three days by using Trypan blue dye exclusion test and XTT assay. Cytotoxic effects of rapamycin in DU145, PC3 and LNCAP cells were detected in time and dose dependent manner with the IC50 doses within the range of 1–100 nM. As the results were evaluated, IC50 doses in the DU145, PC3, and LNCaP cells were detected as 10, 25, and 50 nM, respectively. The mean relative ratios of URGCP gene expression in DU145, LNCAP and PC3 cells were found as −1.48, 6.59 and −13.00, respectively, when compared to rapamycin-free cells. The False Discovery Rate adjusted p value in DU145, LNCAP and PC3 were 1.25 × 10−5, 2.20 × 10−8 and 6.20 × 10−9, respectively. When the URGCP gene expression level is compared between the dose and control group, we found that URGCP gene expression was significantly decreased in dose groups of DU145 and PC3 cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Amato RJ, Jac J, Mohammad T, Saxena S (2008) Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 6:97–102

    Article  PubMed  CAS  Google Scholar 

  2. Chin JL, Reiter RE (2004) Molecular markers and prostate cancer prognosis. Clin Prostate Cancer 3:157–164

    Article  PubMed  CAS  Google Scholar 

  3. Garcia JA, Danielpour D (2008) Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7(6):1347–1354

    Article  PubMed  CAS  Google Scholar 

  4. Goktas S, Crawford ED (1999) Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 26:162–173

    PubMed  CAS  Google Scholar 

  5. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivières S, Mercep L, Ferrari S (1998) Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273:14424–14429

    Article  PubMed  CAS  Google Scholar 

  6. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L et al (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217–227

    Article  PubMed  CAS  Google Scholar 

  7. Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y (2007) An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett 253:236–248

    Article  PubMed  CAS  Google Scholar 

  8. Huang J, Zhu B, Lu L, Lian Z, Wang Y, Yang X, Satiroglu-Tufan NL, Liu J, Luo Z (2009) The expression of novel gene URG4 in osteosarcoma: correlation with patients’ prognosis. Pathology 41:49–54

    Google Scholar 

  9. Hussain M, Wolf M, Marshall E, Crawford ED, Isenberger M (1994) Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a southwest oncology group report. J Clin Oncol 12:1868–1875

    PubMed  CAS  Google Scholar 

  10. Kantoff PW, Halabi S, Conaway M (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506–2513

    PubMed  CAS  Google Scholar 

  11. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K et al (2006) Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66:1203–1212

    Article  PubMed  CAS  Google Scholar 

  12. Lee CH, Inoki K, Guan KL (2007) mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 47:443–467

    Article  PubMed  CAS  Google Scholar 

  13. Masiello D, Mohi MG, McKnight NC, Smith B, Neel BG, Balk SP et al (2007) Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther 6:195–201

    Article  PubMed  CAS  Google Scholar 

  14. Nozawa H, Watanabe T, Nagawa H (2007) Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 251:105–113

    Article  PubMed  CAS  Google Scholar 

  15. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45

    Article  PubMed  CAS  Google Scholar 

  16. Sandler HM, Narayan S, Smith DC (2003) Combined modality treatment for prostate cancer: role of chemotherapy. Semin Oncol 30:95–100

    Article  PubMed  CAS  Google Scholar 

  17. Satiroglu-Tufan NL, Dodurga Y, Gok D, Cetinkaya A, Feitelson MA (2010) RNA interference-mediated URG4 gene silencing diminishes cyclin D1 mRNA expression in HepG2 cells. Genet Mol Res 9(3):1557–1567

    Article  PubMed  CAS  Google Scholar 

  18. Song J, Xie H, Liany Z, Yang G, Du R, Du Y, Zou X, Jin HF, Gao J, Liu J, Fan D (2006) Enhanced cell survival of gastric cancer cells by a novel gene URG4. Neoplasia 8:995–1002

    Article  PubMed  Google Scholar 

  19. Tufan NL, Lian Z, Liu J, Pan J, Arbuthnot P, Kew M, Clayton MM, Zhu M, Feitelson MA (2002) Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia 4:355–368

    Article  PubMed  CAS  Google Scholar 

  20. Tufan NL, Lian Z, Liu J, Pan J, Arbuthnot P, Kew M, Clayton MM, Zhu M, Feitelson MA (2002) Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia 4:355–368

    Article  PubMed  CAS  Google Scholar 

  21. Velcheti V, Karnik S, Bardot SF, Prakash O (2008) Pathogenesis of prostate cancer: lessons from basic research. Ochsner J 8(4):213–218

    PubMed  Google Scholar 

  22. Wang W, Jia WD, Xu GL, Wang ZH, Li JS, Ma JL et al (2009) Antitumoral activity of rapamycin mediated through inhibition of HIF-1 alpha and VEGF in hepatocellular carcinoma. Dig Dis Sci 54:2128–2136

    Article  PubMed  CAS  Google Scholar 

  23. Zhang JF, Liu JJ, Lu MQ, Cai CJ, Yang Y, Li H et al (2007) Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transpl Immunol 17:162–168

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biology, Pamukkale University School of Medicine, Denizli, Turkey

    Yavuz Dodurga

  2. Department of Medical Biology, Ege University School of Medicine, Izmir, Turkey

    Çığır Biray Avcı, Sunde Yılmaz Susluer & Cumhur Gündüz

  3. Department of Medical Genetics, Pamukkale University School of Medicine, Denizli, Turkey

    N. Lale Şatıroğlu Tufan

Authors
  1. Yavuz Dodurga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Çığır Biray Avcı
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sunde Yılmaz Susluer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Lale Şatıroğlu Tufan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cumhur Gündüz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yavuz Dodurga.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dodurga, Y., Avcı, Ç.B., Susluer, S.Y. et al. The expression of URGCP gene in prostate cancer cell lines: correlation with rapamycin. Mol Biol Rep 39, 10173–10177 (2012). https://doi.org/10.1007/s11033-012-1891-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-012-1891-6

Keywords

Search

Navigation